An interventional study of False Safety Behavioral Elimination Treatment (FSET) and Enhanced Standard Care in Anxiety Disorders and Post-traumatic Stress Disorder, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Anxiety Disorders by Massachusetts General Hospital — 14 open to participants now, 20 under way, none of them phase 3. Anxiety Disorders · Massachusetts General Hospital.
Among the 67 studies in Anxiety Disorders by Massachusetts General Hospital, this one is the 33rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 6 that started in 2024, is one of 40 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 56th registered.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
Browse Anxiety Disorders studies →14 of the 67 studies in Anxiety Disorders by Massachusetts General Hospital are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 12–17
Massachusetts General Hospital · Sites in United States
Ages 7–17
Massachusetts General Hospital · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 947 Anxiety Disorders studies recruiting now, 423 (45%) set no upper age limit and 455 (48%) stop at 75 or younger; 233 take children under 18; 319 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 4 · Phase 4 11
First in 1998; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Median enrollment 63 across the 64 interventional studies, 123 across the 2 observational. Of the 44 that completed or were terminated, 27 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
8 of the studies in Anxiety Disorders by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07639827Massachusetts General HospitalA Study of a Mental Fitness Intervention for Anesthesiology Resident Wellbeing and Self-Compassion | 2027-01 |
| NCT06226155Massachusetts General HospitalAdaptation of an Intervention Addressing Barriers to PrEP Use Among Pregnant Women in Zimbabwe | 2027-01-01 |
| NCT06316804Massachusetts General HospitalMobile Mental Health Stigma Reduction Intervention Among Black Adults | 2027-01-01 |
| NCT06654414Massachusetts General HospitalAdapting and Pilot Testing a Skills-based Smoking Cessation Intervention to Address Developmental and Health-related Stress Among Adults Who Smoke | 2027-03-31 |
| NCT06557005Massachusetts General HospitalFacilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions | 2027-05-23 |
Add all 8 to your calendar (.ics) → With an account.
Among the 67 studies in Anxiety Disorders by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the use of a brief transdiagnostic treatment for anxiety disorders and (post-traumatic stress disorder (PTSD) in South Africa. The intervention will be delivered by non-specialist providers (e.g., nurses) in primary care clinics. The brief intervention group will be compared to an enhanced standard care control group.
Post-traumatic stress disorder (PTSD) and anxiety disorders are highly prevalent and a leading cause of disability in low and middle-income countries (LMICs). Despite the development of evidence-based treatments (EBTs), an overwhelming majority of those in need (i.e., 85%) in LMICs do not receive treatment and, when they do, it is not empirically based. Despite the clear need for EBTs in LMICs, there are three primary barriers associated with the implementation of EBTs in these areas. These barriers include: (1) EBTs tend to be single disorder focused only treating one disorder at a time, (2) they are long in duration (e.g., 12-16 treatment sessions to treat one disorder), and (3) they tend to be complex and require a high level of skill to administer. Given the low availability of highly trained providers in LMICs, using an approach that is brief, culturally congruent, and less complex than typical EBTs is ideal for reducing these barriers. The current study aims to evaluate the use of a brief transdiagnostic treatment for anxiety disorders and PTSD (False Safety Behavior Elimination Treatment; F-SET) in South African primary care clinics. The current study is a Type 1 hybrid effectiveness-implementation trial assessing the effectiveness of the adapted brief transdiagnostic intervention and to explore facilitators and barriers to implementation. The adapted intervention is being compared to an enhanced standard care control condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The anxiety disorders and post-traumatic stress disorder (PTSD) transdiagnostic treatment (FSET) is brief, 5-session, cognitive-behavioral intervention designed to treat symptoms associated with anxiety disorders and PTSD. The treatment is administered by lay providers (e.g., nurses) in primary care clinics in South Africa.
Behavioral: False Safety Behavioral Elimination Treatment (FSET)
The enhanced standard care group is the condition. Those in the enhanced standard care control group will receive standard care plus referrals. Upon completion of the study, they will be offered the anxiety disorder and post-traumatic stress disorder treatment (FSET).
Behavioral: Enhanced Standard Care
5-session transdiagnostic treatment for anxiety disorders and post-traumatic stress disorder (PTSD)
Participants in the enhanced standard care control group will receive treatment as usual and a list referrals.
Structured Clinical Interview for the DSM-5 (SCID-5)
Diagnostic assessment assessing the presence or absence of a mental health diagnosis.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Clinician-Administered PTSD Scale for the DSM-5 (CAPS)
Diagnostic assessment assessing the presence or absence of post-traumatic stress disorder (PTSD)
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Work Social Adjustment Scale (WSAS)
Assessment of functional impairment. Scores range from 0 to 40 with higher scores indicating higher levels of functional impairment.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
General Anxiety Disorder-7 (GAD-7)
General measure of anxiety. Scores range from 0 to 21 with higher scores indicating greater level of anxiety.
Time frame: pre-treatment, immediately after the last treatment session, and 3-month follow-up
Beck Anxiety Inventory (BAI)
Measure of anxiety symptoms. Scores range from 0 to 63 with higher scores indicating greater levels of anxiety.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Safety Aid Scale (SAS)
Assessment of safety aid utilization and avoidance in anxiety disorders and PTSD. Higher scores indicate greater safety aid utilization.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Post-traumatic Disorder Checklist (PCL-5 PTSD Checklist (PCL-5)
PTSD symptom measure. Scores range from 0 to 80 with higher scores indicating greater level of post-traumatic stress symptoms.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Patient Health Questionnaire - 9 (PHQ-9)
Measure of emotional distress. Scores range from 0 to 20 with higher scores indicating greater emotional distress.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Beck Depression Inventory (BDI)
Measure of depressive symptoms. Scores range from 0 to 63 with higher scores indicating greater levels of depression.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Anxiety Sensitivity Index -3
Assessment of anxiety sensitivity. Scores range from 0 to 72 with higher scores indicated higher levels of anxiety sensitivity.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Life Events Checklist (LEC)
Assessment of exposure to traumatic events. Endorsement of events indicates the degree to which one has been exposed to traumatic events.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Alcohol Use Disorders Identification Test (AUDIT)
Assessment of alcohol use. Scores range from 0 to 40 with higher scores indicating possible problematic alcohol use.
Time frame: pre-treatment, post-treatment (immediately after the last treatment session), and 3-month follow-up
Ran from May 2024 to primary completion in Oct 2026, 29 months.
Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 29 months is above that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jul 2026 → Oct 2026 and completion Dec 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →